Expression of activator protein-1 (AP-1) family members in breast cancer

被引:72
作者
Kharman-Biz, Amirhossein [1 ,2 ]
Gao, Hui [1 ]
Ghiasvand, Reza [2 ,3 ]
Zhao, Chunyan [1 ]
Zendehdel, Kazem [2 ]
Dahlman-Wright, Karin [1 ]
机构
[1] Karolinska Inst, Dept Biosci & Nutr, S-14183 Huddinge, Sweden
[2] Univ Tehran Med Sci, Canc Inst Iran, Canc Res Ctr, Tehran, Iran
[3] Univ Oslo, Inst Basic Med Sci, Dept Biostat, Oslo, Norway
关键词
AP-1 family members; Breast cancer; Estrogen receptor; Progesterone receptor; CELL-PROLIFERATION; ESTROGEN-RECEPTOR; FOS; FRA-1; PROGESTERONE; PROGRESSION; PROGNOSIS; SURVIVAL; INVASION; JUN;
D O I
10.1186/1471-2407-13-441
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The activator protein-1 (AP-1) transcription factor is believed to be important in tumorigenesis and altered AP-1 activity was associated with cell transformation. We aimed to assess the potential role of AP-1 family members as novel biomarkers in breast cancer. Methods: We studied the expression of AP-1 members at the mRNA level in 72 primary breast tumors and 37 adjacent non-tumor tissues and evaluated its correlation with clinicopathological parameters including estrogen receptor (ER), progesterone receptor (PR) and HER2/neu status. Expression levels of Ubiquitin C (UBC) were used for normalization. Protein expression of AP-1 members was assessed using Western blot analysis in a subset of tumors. We used student's t-test, one-way ANOVA, logistic regression and Pearson's correlation coefficient for statistical analyses. Results: We found significant differences in the expression of AP-1 family members between tumor and adjacent non-tumor tissues for all AP-1 family members except Fos B. Fra-1, Fra-2, Jun-B and Jun-D mRNA levels were significantly higher in tumors compared to adjacent non-tumor tissues (p < 0.001), whilst c-Fos and c-Jun mRNA levels were significantly lower in tumors compared with adjacent non-tumor tissues (p < 0.001). In addition, Jun-B overexpression had outstanding discrimination ability to differentiate tumor tissues from adjacent non-tumor tissues as determined by ROC curve analysis. Moreover, Fra-1 was significantly overexpressed in the tumors biochemically classified as ERa negative (p = 0.012) and PR negative (p = 0.037). Interestingly, Fra-1 expression was significantly higher in triple-negative tumors compared with luminal carcinomas (p = 0.01). Conclusions: Expression levels of Fra-1 and Jun-B might be possible biomarkers for prognosis of breast cancer.
引用
收藏
页数:10
相关论文
共 30 条
[1]   Endocrine-responsive breast cancer and strategies for combating resistance [J].
Ali, S ;
Coombes, RC .
NATURE REVIEWS CANCER, 2002, 2 (02) :101-+
[2]   THE ROLE OF JUN, FOS AND THE AP-1 COMPLEX IN CELL-PROLIFERATION AND TRANSFORMATION [J].
ANGEL, P ;
KARIN, M .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1072 (2-3) :129-157
[3]  
Bamberger AM, 1999, INT J CANCER, V84, P533, DOI 10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO
[4]  
2-J
[5]   FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells [J].
Belguise, K ;
Kersual, N ;
Galtier, F ;
Chalbos, D .
ONCOGENE, 2005, 24 (08) :1434-1444
[6]   The PKCθ pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells [J].
Belguise, K. ;
Milord, S. ;
Galtier, F. ;
Moquet-Torcy, G. ;
Piechaczyk, M. ;
Chalbos, D. .
ONCOGENE, 2012, 31 (47) :4889-4897
[7]   FRA-I protein overexpression is a feature of hyperplastic and neoplastic breast disorders [J].
Chiappetta, Gennaro ;
Ferraro, Angelo ;
Botti, Gerardo ;
Monaco, Mario ;
Pasquinelli, Rosa ;
Vuttariello, Emilia ;
Arnaldi, Liliane ;
Di Bonito, Maurizio ;
D'Aiuto, Giuseppe ;
Pierantoni, Giovanna Maria ;
Fusco, Alfredo .
BMC CANCER, 2007, 7 (1)
[8]   International Union of Pharmacology.: LXIV.: Estrogen receptors [J].
Dahlman-Wright, Karin ;
Cavailles, Vincent ;
Fuqua, Suzanne A. ;
Jordan, V. Craig ;
Katzenellenbogen, John A. ;
Korach, Kenneth S. ;
Maggi, Adriana ;
Muramatsu, Masami ;
Parker, Malcolm G. ;
Gustafsson, Jan-Ake .
PHARMACOLOGICAL REVIEWS, 2006, 58 (04) :773-781
[9]   Effects of young age at presentation on survival in breast cancer [J].
El Saghir, Nagi S. ;
Seoud, Muhieddine ;
Khalil, Mazen K. ;
Charafeddine, Maya ;
Salem, Ziad K. ;
Geara, Fady B. ;
Shamseddine, Ali I. .
BMC CANCER, 2006, 6 (1)
[10]   Testing for HER2 status [J].
Hanna, W .
ONCOLOGY, 2001, 61 :22-30